

iBio, Inc.  
Form 10-K/A  
October 15, 2012

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**FORM 10-K/A**

**(Amendment No. 1)**

**Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**  
For the fiscal year ended June 30, 2012

OR

**Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 001-35023

iBio, Inc.  
(Exact name of small business registrant in its charter)

Delaware 26-2797813

(State or other jurisdiction of (I.R.S. Employer Identification  
incorporation or organization) No.)

9 Innovation Way, Suite  
100, Newark, DE 19711

(Address of principal executive  
offices) (Zip Code)

**(302) 355-0650**

(Registrant's telephone number, including Area Code)

Securities registered under Section 12(b) of the Exchange Act:

Title of Each Class	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NYSE MKT

Securities registered under Section 12(g) of the Exchange Act: None



Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes  No

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to

such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to

the best of  
Registrant's  
knowledge, in  
definitive  
proxy or  
information  
statements  
incorporated  
by reference  
in Part III of  
this Form  
10-K or any  
amendment to  
this Form  
10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer", "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated Filer   
Accelerated Filer   
Non-accelerated Filer   
Smaller reporting company

Indicate by  
check mark  
whether the  
registrant is a  
shell  
company (as  
defined in  
Rule 12b-2 of  
the Exchange  
Act).

Yes  No

The  
aggregate  
market value  
of the voting  
stock held by  
non-affiliates  
of the  
Registrant  
based on the  
trading price  
of the  
Registrant's

Common  
Stock on June  
30, 2012 was  
\$22,339,800

The number  
of shares  
outstanding  
of each of the  
Registrant's  
classes of  
common  
equity, as of  
the latest  
practicable  
date:

Class	Outstanding at September 14, 2012
Common Stock, \$0.001 par value	47,767,095 Shares

**Explanatory Note**

The purpose of this Amendment No. 1 to the Annual Report on Form 10-K of iBio, Inc. for the year ended June 30, 2012, filed with the Securities and Exchange Commission on October 12, 2012 (the "Form 10-K"), is solely to furnish Exhibit 101 to the Form 10-K in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the financial statements and related notes from the Form 10-K formatted in XBRL (eXtensible Business Reporting Language).

No other changes have been made to the Form 10-K. This Amendment No. 1 to the Form 10-K speaks only as of the original filing date of the Form 10-K, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-K.

---

**Item 15. Exhibits and Financial Statement Schedules**

Number	Description
3.1	Certificate of Incorporation of the Company (1)
3.2	Certificate of Amendment of the Certificate of Incorporation of the Company (2)
3.3	Bylaws of the Company (3)
4.1	Form of Common Stock Certificate (1)
4.2	Form of Investor Warrant (2008) (4)
4.3	Form of Investor Warrant (2010) (5)
10.1	Technology Transfer Agreement, dated as of January 1, 2004, between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. (6)
10.2	Non-Standard Navy Cooperative Research and Development Agreement, dated August 17, 2004, between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. (6)
10.3	Supply License Agreement, dated as of March 22, 2006, between the Company and Mannatech, Inc.



- 10.4 (6)  
Form of  
Registration Rights  
Agreement (2008)
- 10.5 (4)  
Form of  
Registration Rights  
Agreement (2010)
- 23.1 (5)  
Consent of  
Independent  
Registered Public  
Accounting Firm
- 31.1 (7)  
Certification of  
Periodic Report by  
Chief Executive  
Officer Pursuant to  
Rule 13a-14 and  
15d-14 of the  
Securities  
Exchange Act of  
1934, as adopted  
pursuant to Section  
302 of the  
Sarbanes-Oxley  
Act of 2002 (7)
- 31.2 Certification of  
Periodic Report by  
Chief Financial  
Officer Pursuant to  
Rule 13a-14 and  
15d-14 of the  
Securities  
Exchange Act of  
1934, as adopted  
pursuant to Section  
302 of the  
Sarbanes-Oxley  
Act of 2002 (7)
- 32.1 Certification of  
Periodic Report by  
Chief Executive  
Officer Pursuant to  
18 U.S.C. Section  
1350, as adopted  
pursuant to Section  
906 of the  
Sarbanes-Oxley  
Act of 2002 (7)
- 32.2

Certification of  
Periodic Report by  
Chief Financial  
Officer Pursuant to  
18 U.S.C. Section  
1350, as adopted  
pursuant to Section  
906 of the  
Sarbanes-Oxley  
Act of 2002 (7)  
XBRL

101.INS INSTANCE  
DOCUMENT (8)

XBRL

101.SCH TAXONOMY  
EXTENSION  
SCHEMA (8)

XBRL

TAXONOMY

101.CAL EXTENSION  
CALCULATION  
LINKBASE (8)

XBRL

TAXONOMY

101.DEF EXTENSION  
DEFINITION  
LINKBASE (8)

XBRL

TAXONOMY

101.LAB EXTENSION  
LABEL  
LINKBASE (8)

XBRL

TAXONOMY

101.PRE EXTENSION  
PRESENTATION  
LINKBASE (8)

- (1) Incorporated herein by reference to the Company's Form 10-12G filed with the SEC on July 11, 2008.
- (2) Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on December 15, 2010.
- (3) Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on August 14, 2009.
- (4) Incorporated herein by reference to the Company's Current Report on Form 8-K filed with the SEC on August 21, 2008.
- (5)

Edgar Filing: iBio, Inc. - Form 10-K/A

Incorporated herein by reference to the Company's Quarterly Report on Form 10-Q filed with the SEC on November 15, 2010.

- (6) Incorporated herein by reference to the Company's Form 10-12G filed with the SEC on June 18, 2008.
  - (7) Previously filed.
  - (8) In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise Exhibit 101 in this report on Form 10-K shall be deemed "furnished" and not "filed."
-

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on October 12, 2012.

iBio, Inc.

By: /s/ Robert B. Kay  
 Robert B. Kay  
 Chief Executive Officer

In accordance with the Securities Exchange Act, this report has been signed below by the following persons on behalf of iBio, Inc. and in the capacities and on the dates indicated:

Signature	Title	Date
/s/ Robert B. Kay Robert B. Kay	Chief Executive Officer and Director (Principal Executive Officer)	October 12, 2012
/s/ Glenn Chang Glenn Chang	Director	October 12, 2012
/s/ Arthur Y. Elliott Arthur Y. Elliott, Ph.D.	Director	October 12, 2012
/s/ James T. Hill General James T. Hill (Ret.)	Director	October 12, 2012
/s/ Douglas Beck Douglas Beck, CPA	Chief Financial Officer (Principal Financial and Accounting Officer)	October 12, 2012
/s/ John D. McKey, Jr. John D. McKey, Jr.	Director	October 12, 2012
/s/ Philip K. Russell Philip K. Russell, M.D.	Director	October 12, 2012
/s/ Jules Müsing Jules Müsing	Director	October 12, 2012